New developments in angiogenesis: a major mechanism for tumor growth and target for therapy.
Imperial Cancer Research Fund, Molecular Oncology Laboratory, University of Oxford, John Radcliffe Hospital, England.
A
A
Jones
A L
AL
Harris
D043925:Angiogenesis Inducing Agents / Q000502:physiology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D016228:Endothelial Growth Factors / Q000494:pharmacology / Q000502:physiology; D015316:Genetic Therapy; D006801:Humans; D008222:Lymphokines / Q000494:pharmacology / Q000502:physiology; D009369:Neoplasms / Q000098:blood supply* / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology; D009857:Oncogenes / Q000502:physiology; D010447:Peptide Hydrolases; D017466:Receptors, Endothelin / Q000187:drug effects / Q000502:physiology; D015398:Signal Transduction; D015854:Up-Regulation; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D043925:Angiogenesis Inducing Agents; D000970:Antineoplastic Agents; D016228:Endothelial Growth Factors; D008222:Lymphokines; D017466:Receptors, Endothelin; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D010447:Peptide Hydrolases